Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11391MR)

This product GTTS-WQ11391MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11391MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15344MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ13680MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ9224MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ13713MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ14179MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ8226MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ15524MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ2050MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AHLX-20
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW